Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2,-3, and-7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptore-positive, HER2-negative (HR+/HER2L) advanced breast cancer (ABC)

Simple item page
dc.conference.dateSEP 19-OCT 18, 2020
dc.conference.titleESMO Virtual Congress
dc.contributor.authorFasching, P. A.
dc.contributor.authorBardia, A.
dc.contributor.authorNusch, A.
dc.contributor.authorJerusalem, G.
dc.contributor.authorChan, A.
dc.contributor.authorEl Saghir, N.
dc.contributor.authorAlba, E.
dc.contributor.authorIm, S-A.
dc.contributor.authorJanni, W.
dc.contributor.authorChandiwana, D.
dc.contributor.authorLanoue, B.
dc.contributor.authorThuerigen, A.
dc.contributor.authorGaur, A.
dc.contributor.authorHarbeck, N.
dc.contributor.authoraffiliation[Fasching, P. A.] Univ Klinikum Erlangen, Dept Gynecol & Obstet, Erlangen, Germany
dc.contributor.authoraffiliation[Bardia, A.] Massachusetts Gen Hosp, Ctr Canc, Med Oncol, Boston, MA USA
dc.contributor.authoraffiliation[Jerusalem, G.] Ctr Hosp Univ Sart Tilman, Med Oncol Dept, Liege, Belgium
dc.contributor.authoraffiliation[Chan, A.] Breast Canc Res Ctr WA, Oncol, Perth, WA, Australia
dc.contributor.authoraffiliation[Chan, A.] Sch Med, Perth, WA, Australia
dc.contributor.authoraffiliation[El Saghir, N.] Amer Univ Beirut, Med Ctr, Oncol, Beirut, Lebanon
dc.contributor.authoraffiliation[Alba, E.] Hosp Clin Univ Virgen de la Victoria, Dept Med Oncol, Malaga, Spain
dc.contributor.authoraffiliation[Im, S-A.] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
dc.contributor.authoraffiliation[Im, S-A.] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea
dc.contributor.authoraffiliation[Janni, W.] Ulm Univ Hosp, Frauenklin, Ulm, Germany
dc.contributor.authoraffiliation[Chandiwana, D.] Novartis Pharmaceut, Oncol, E Hanover, NJ USA
dc.contributor.authoraffiliation[Lanoue, B.] Novartis Pharmaceut, Oncol, E Hanover, NJ USA
dc.contributor.authoraffiliation[Thuerigen, A.] Novartis Healthcare Pvt Ltd, Oncol, Basel, NJ, Switzerland
dc.contributor.authoraffiliation[Gaur, A.] Novartis Healthcare Pvt Ltd, Oncol, Hyderabad, Telangana, India
dc.contributor.authoraffiliation[Harbeck, N.] Ludwig Maximilians Univ Grosshadern, Breast Ctr, Munich, Germany
dc.contributor.funderNovartis Pharmaceuticals Corporation
dc.date.accessioned2025-01-07T15:04:03Z
dc.date.available2025-01-07T15:04:03Z
dc.date.issued2020-09-01
dc.identifier.doi10.1016/j.annonc.2020.08.378
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753420403746/pdf
dc.identifier.urihttps://hdl.handle.net/10668/26855
dc.identifier.wosID573469100276
dc.issue.number4
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen de la Victoria
dc.page.numberS350-S351
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titlePooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2,-3, and-7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptore-positive, HER2-negative (HR+/HER2L) advanced breast cancer (ABC)
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number31
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen de la Victoria

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía